Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 388

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 388
---
(1.0)%Other income (expense)Interest income324 826 (502)(60.8)%Other income, net— 8 (8)(100.0)%Net loss$(14,433)$(14,079)$(354)2.5 %

Research and Development

The following table summarizes the components of our research and development expenses for the periods indicated:

Three Months Ended June 30,Change20252024$%(in thousands, except percentages)Direct research and development expenses by program:atebimetinib (IMM-1-104)$5,169 $3,807 $1,362 35.8 %IMM-6-415279 1,132 (853)(75.4)%Other programs1,178 1,485 (307)(20.7)%Indirect research and development expenses:Employee-related costs2,830 3,147 (317)(10.1)%Stock-based compensation expense610 678 (68)(10.0)%Facilities and other expenses327 341 (14)(4.1)%Depreciation/amortization61 62 (1)(1.6)%Total research and development$10,454 $10,652 $(198)(1.9)%

Research and development expenses decreased by approximately $0.2 million, or 1.9%, to approximately $10.5 million for the three months ended June 30, 2025 as compared to approximately $10.7 million for the three months ended June 30, 2024. The decrease of approximately $0.2 million was primarily due to a decrease in indirect research and development expenses of approximately $0.4 million, which was primarily driven by decreased employee-related costs (including due to a lower employee headcount) of $0.3 million, stock-based compensation costs of $0.1 million, in addition to facilities and other expenses of $15 thousand. The remaining variance was driven by an increase of approximately $0.2 million related to direct research and development expenses, including a $1.4 million increase in expenses related to atebimetinib (IMM-1-104) offset by a $0.9 million decrease in expenses related to IMM-6-415, and decreased preclinical spend of approximately $0.3 million due to the Company's prioritization of atebimetinib. 

28

General and Administrative

The following table summarizes the